Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Hodgkin’s Lymphoma | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

Login to access report north_east
Contact sales account_box

The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the label expansion of Adcetris and the approval of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).

CONTENT OVERVIEW

From disease basics to insightful analysis of market dynamics, Hodgkin’s lymphoma | Disease Landscape & Forecast | US and EU5 provides comprehensive disease coverage addressing critical aspects of the Hodgkin’s lymphoma pharmaceutical market based on primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug-treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a topline review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.

WHAT YOU WILL LEARN IN THIS CONTENT

  • How large is the drug-treatable Hodgkin’s lymphoma population and how will drug-treatment rates change over time?
  • What is the current state of treatment in Hodgkin’s lymphoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in Hodgkin’s lymphoma? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the Hodgkin’s lymphoma market, and how will the market evolve over the forecast period?

KEY DRUGS COVERED

Adcetris, Opdivo, Keytruda, Farydak, Rituxan/MabThera

KEY COMPANIES MENTIONED

  • Seattle Genetics
  • Takeda
  • Bristol-Myers Squibb
  • Merck & Co.
  • Novartis
  • Roche/Genentech
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…
north_east
Report
Muscular Dystrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…
north_east
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
north_east
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
north_east
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east